Health Care · Surgical & Medical Instruments & Apparatus

SNWV SANUWAVE Health, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1417663126 filings
Russell 2000

SNWV at a glance

SANUWAVE Health, Inc. (SNWV, SEC CIK 1417663) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), SANUWAVE Health, Inc. (SNWV) reported revenue of $44.1 million (up 35.0% from FY2024) and net income of $11.8 million. Diluted EPS was $0.41.
  • As of September 30, 2026, 13 institutional investment managers tracked by SignalX reported holding SANUWAVE Health, Inc. (SNWV) shares worth $3.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$44.1M
+35.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
13 funds
$3.7M · −1 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $8.6M, down 24% YoY from $11.3M
  • Gross margin 77% vs 78% YoY, operating loss $1.1M vs operating income $0.9M
  • Worst performer Ultramist® systems: $1.2M, down 73% from $4.4M
  • Cash $6.6M, operating cash outflow $29K, financing outflow $4.6M
  • Near-term headwinds: weaker capital sales, used-system availability, Nasdaq MVLS compliance by March 22, 2027

Risk Factors

  • Newly added covenant risk: JPM Credit Agreement breach as of September 30, 2026, waived under October 28 amendment
  • Reimbursement risk: CPT 97610 Medicare payment falling to $314.54 in 2027 from $397.81 in 2026
  • Regulatory risk: CMS estimates skin-substitute reimbursement changes reduce Medicare spending nearly 90%
  • Market risk: Customer reimbursement pressure contributed to deferred or reduced capital purchases during 2026
  • Nasdaq compliance risk: MVLS below $50.0 million threshold, with compliance deadline March 22, 2027

AI summary of the SNWV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Business update conference call scheduled November 11, 2026 at 8:30 a.m. EST

Item EX-99.1: Item EX-99.1

  • Q3 revenue $8.6M, down 24% from $11.3M, reflecting sharply weaker Ultramist system demand
  • Ultramist systems sold fell to 40 from 155, while applicator revenue increased 2% to $6.9M, highlighting recurring-revenue resilience
Filed Oct 28, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Lenders waived fixed-charge coverage default risk for the twelve months ending September 30, 2026
  • Written lender consent now required for permitted acquisitions and certain equity repurchases
Filed Sep 25, 2026Full analysis →

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • Nasdaq MVLS below $50 million for 30 consecutive business days, triggering a continued-listing deficiency
  • Common stock remains listed on Nasdaq Global Market with no immediate delisting

AI summaries of SNWV 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SNWV

Don't miss the next SNWV filing

  • Alerts as it files. A push when SNWV files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SNWV, by share count.
  • Ask anything. An AI agent that reads every SNWV filing and answers with sources.

SNWV alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Miller Ian D.ASep 30, 2026-
Bazar Gregory MatthewASep 30, 2026-
Tyler JamesASep 30, 2026-
FRANK MORGAN C.ASep 30, 2026-
Blizard JeffreyASep 30, 2026-
Bazar Gregory MatthewAJun 30, 2026-
Blizard JeffreyAJun 30, 2026-
Tyler JamesAJun 30, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$32.6M$44.1M
Gross Profit-$24.6M$34.0M
Operating Income-$5.4M$4.9M
Net Income--$31.4M$11.8M
Gross Margin-75.2%77.1%
Op. Margin-16.6%11.2%
Net Margin--96.1%26.8%
Balance Sheet
Total Assets-$30.1M$37.3M
Equity-$44.5M-$12.7M$1.6M
ROE-246.7%729.6%
Per Share
EPS-$-7.03$0.41
Cash Flow
Operating CF-$2.5M$3.9M
CapEx$0$490K$1.9M

Source: XBRL data in SANUWAVE Health, Inc. (SNWV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SNWV share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SNWV shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202613$3.7M
Q2 202614$7.9M
Q1 202616$21.0M
Q4 202514$36.8M
Q3 202514$46.9M
Q2 202513$33.2M
Q1 20256$10.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 90 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SNWV filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 10, 2026Analysis
8-KNov 10, 2026Analysis-
8-KOct 28, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
8-KSep 25, 2026Analysis-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
8-KJul 13, 2026Analysis-
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
8-KJun 16, 2026Analysis-
8-KJun 15, 2026Analysis-
8-KMay 12, 2026Analysis
10-QMay 12, 2026Analysis
4May 4, 2026--
4Apr 30, 2026--
4Apr 21, 2026--
8-KApr 16, 2026Analysis-

Related Health Care companies

All Health Care →

SNWV SEC filings: frequently asked questions

Which institutions hold SNWV stock?

As of September 30, 2026, the largest SANUWAVE Health, Inc. (SNWV) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.6 million), BlackRock ($673,000), D.E. Shaw & Co ($279,000), JPMorgan Chase & Co ($238,000), State Street Corp ($147,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SNWV's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), SANUWAVE Health, Inc. (SNWV) reported revenue of $44.1 million (up 35.0% from FY2024) and net income of $11.8 million. Diluted EPS was $0.41. The figures come from the XBRL data in the 10-K.

What did SNWV report in its latest 8-K?

SANUWAVE Health, Inc. (SNWV) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest SNWV SEC filings?

SANUWAVE Health, Inc. (SNWV) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on October 2, 2026.

What is SNWV's SEC CIK number?

SANUWAVE Health, Inc. (SNWV)'s SEC Central Index Key (CIK) is 1417663. EDGAR lists every SNWV filing under that number.

Ask anything about SNWV

The research agent reads SNWV's filings, financials, insider trades and 13F holders, then answers with sources.